New phenotypes of SMA now cross over traditional subtypes of SMA, so it is more appropriate to rely on a combination of age of onset, number of SMN2 copies, and age at initiation of drug treatment, rather than traditional subtypes, to define a clinical phenotype of SMA [12]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.